Exchange: NASDAQ·Updated 07:41 PM EDT
Latest Earnings Results: Q1 '26

Reported: May 08

Estimated EPS

-$0.04

Reported EPS

-$0.10

Surprise

-169.23%

Estimated Rev

$84.52M

Reported Rev

$80.1M

Surprise

-5.23%

$ESPR Q1 '26 Earnings Results & Recap • Reported GAAP EPS of -$0.10 up 52.38% YoY • Reported revenue of $80.1M up 23.25% YoY • Esperion Therapeutics expects continued operating losses and consistent research and development expenses in 2026, with selling, general and administrative expenses anticipated to increase slightly in 2026.

Generated by Stocktwits using AI and company-reported earnings data for Q1 '26. This recap is intended to help readers understand the quarter quickly. Verify key figures in the linked source materials; the summary may contain errors and is not investment advice.

Historical Earnings

Quarterly

Annual

EPS

Revenue

Fiscal PeriodEstimatedReportedSurpriseResult
Q2 '26
$0.02
--
--
N/A
Q1 '26
-$0.04
-$0.10
-169.23%
MISSED
Q4 '25
$0.24
$0.22
-9.59%
MISSED
Q3 '25
-$0.08
-$0.16
-104.27%
MISSED
Q2 '25
-$0.15
-$0.02
86.27%
BEAT

Advertisement|Remove ads.